Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention

EC Vamvakas, MA Blajchman - Blood, The Journal of the …, 2009 - ashpublications.org
As the risks of allogeneic blood transfusion (ABT)–transmitted viruses were reduced to
exceedingly low levels in the US, transfusion-related acute lung injury (TRALI), hemolytic …

Transfusion-Transmitted Babesia spp.: Bull's-Eye on Babesia microti

DA Leiby - Clinical microbiology reviews, 2011 - Am Soc Microbiol
Babesia spp. are intraerythrocytic protozoan parasites of animals and humans that cause
babesiosis, a zoonotic disease transmitted primarily by tick vectors. Although a variety of …

Transfusion-associated infections: 50 years of relentless challenges and remarkable progress.

HA Perkins, MP Busch - Transfusion, 2010 - search.ebscohost.com
The article discusses the developments and systematic assessments to respond emerging
transfusion-transmitted infectious diseases (TTIDs) over the past 50 years. The American …

Pathogen inactivation technologies for cellular blood components: an update

P Schlenke - Transfusion Medicine and Hemotherapy, 2014 - karger.com
Nowadays patients receiving blood components are exposed to much less transfusion-
transmitted infectious diseases than three decades before when among others HIV was …

Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality

EC Vamvakas, MA Blajchman - Transfusion medicine reviews, 2010 - Elsevier
After reviewing the relative frequency of the causes of allogeneic blood transfusion-related
mortality in the United States today, we present 6 possible strategies for further reducing …

Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM

J Irsch, L Lin - Transfusion Medicine and Hemotherapy, 2011 - karger.com
Background: The transmission of pathogens via blood transfusion is still a major threat.
Expert conferences established the need for a pro-active approach and concluded that the …

Component pathogen inactivation: a critical review

CV Prowse - Vox sanguinis, 2013 - Wiley Online Library
Background and Objectives Pathogen inactivation (PI)‐treated plasma and platelets are
increasingly becoming the products of choice, where licensed. This review summarizes the …

[HTML][HTML] The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

J Kaiser-Guignard, G Canellini, N Lion, M Abonnenc… - Blood reviews, 2014 - Elsevier
Since 1990, several techniques have been developed to photochemically inactivate
pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The …

A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

JP Cazenave, G Follea, L Bardiaux, JM Boiron… - …, 2010 - Wiley Online Library
BACKGROUND: Pathogen reduction of platelets (PRT‐PLTs) using riboflavin and ultraviolet
light treatment has undergone Phase 1 and 2 studies examining efficacy and safety. This …

Residual risk of transfusion‐transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan

R Taira, M Satake, S Momose, S Hino, Y Suzuki… - …, 2013 - Wiley Online Library
BACKGROUND: Nucleic acid amplification testing (NAT) for hepatitis B virus (HBV) during
blood screening has helped to prevent transfusion‐transmitted HBV infection (TT‐HBV) in …